ASCO 2024: Rakuten’s photoimmunotherapy and Keytruda combo shows efficacy in HNSCC

cafead

Administrator
Staff member
  • cafead   May 28, 2024 at 11:02: PM
via US-based Rakuten Medical has announced positive interim data from the Phase Ib/II trial of its photoimmunotherapy, ASP-1929, in combination with Merck & Co’s Keytruda (pembrolizumab) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC).

article source
 

<